STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

CorMedix Inc. to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 25, 2025

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

CorMedix (Nasdaq: CRMD), a biopharmaceutical company specializing in therapeutic products for life-threatening diseases, has scheduled its Q4 and Full Year 2024 financial results announcement. The company will release its financial performance report before market opens on March 25, 2025, followed by a corporate update conference call at 8:30am Eastern Time.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

BERKELEY HEIGHTS, N.J., March 18, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2024, before the market opens on Tuesday, March 25, 2025, and will host a corporate update conference call at 8:30am Eastern Time.

Tuesday, March 25th @ 8:30am ET
Domestic: 1-844-481-2557
International: 1-412-317-0561
Conference ID: 10197392
Webcast: Webcast Link
   

About CorMedix

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath® (taurolidine and heparin) which was approved by the FDA on November 15, 2023. CorMedix commercially launched DefenCath in inpatient settings in April 2024 and in outpatient settings in July 2024. CorMedix is commencing clinical studies in adult Total Parenteral Nutrition (TPN) patients and pediatric hemodialysis (HD) patient populations in 2025 and also intends to develop DefenCath as a catheter lock solution for use in other therapeutic areas. For more information visit: www.cormedix.com.

Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576


FAQ

When will CorMedix (CRMD) release its Q4 2024 earnings?

CorMedix will release Q4 and Full Year 2024 earnings before market opens on March 25, 2025.

What time is CorMedix (CRMD) Q4 2024 earnings call?

The earnings conference call is scheduled for 8:30am Eastern Time on March 25, 2025.

What period will CorMedix (CRMD) financial results cover?

The financial results will cover Q4 and the full year ended December 31, 2024.

What is CorMedix (CRMD) business focus?

CorMedix is a biopharmaceutical company developing and commercializing therapeutic products for life-threatening diseases and conditions.
Cormedix

NASDAQ:CRMD

CRMD Rankings

CRMD Latest News

CRMD Latest SEC Filings

CRMD Stock Data

740.62M
73.24M
7.56%
46.8%
15.92%
Biotechnology
Pharmaceutical Preparations
Link
United States
BERKELEY HEIGHTS